Oral oncology · 2026
Stroma AReactive invasion Front Areas (SARIFA) in early-stage oral tongue squamous cell carcinoma.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almangush Alhadi, Faisal Muhammad, Haglund Caj, Kowalski Luiz Paulo, Hagström Jaana, Coletta Ricardo D, Mäkitie Antti A, Salo Tuula, Leivo Ilmo
Аннотация
BACKGROUND: Stroma AReactive Invasion Front Areas (SARIFA) has recently been introduced as a prognostic indicator. The prognostic value of SARIFA has not been studied in early-stage oral tongue squamous cell carcinoma (OTSCC).
MATERIAL AND METHODS: A total of 287 cases of early-stage OTSCC were included in this multicenter study. SARIFA was defined as direct contact between tumor cells and the adipose tissue, and was assessed in hematoxylin and eosin (HE)-stained sections.
RESULTS: In early-stage OTSCC, SARIFA-positive tumors were associated with worse disease-specific survival with a hazard ratio (HR) of 1.86 (95% CI 1.06-3.28, P = 0.032), overall survival (HR 1.52, 95% CI 1.06-2.19, P = 0.023) and disease-free survival (HR 1.79, 95% CI 1.09-2.93, P = 0.021).
CONCLUSIONS: SARIFA is a histomorphology-based prognosticator, that can identify cases with early-stage OTSCC who might benefit from a multimodality treatment protocol.
MATERIAL AND METHODS: A total of 287 cases of early-stage OTSCC were included in this multicenter study. SARIFA was defined as direct contact between tumor cells and the adipose tissue, and was assessed in hematoxylin and eosin (HE)-stained sections.
RESULTS: In early-stage OTSCC, SARIFA-positive tumors were associated with worse disease-specific survival with a hazard ratio (HR) of 1.86 (95% CI 1.06-3.28, P = 0.032), overall survival (HR 1.52, 95% CI 1.06-2.19, P = 0.023) and disease-free survival (HR 1.79, 95% CI 1.09-2.93, P = 0.021).
CONCLUSIONS: SARIFA is a histomorphology-based prognosticator, that can identify cases with early-stage OTSCC who might benefit from a multimodality treatment protocol.